Comparative Analysis of Clinical Outcomes after Placement of Enhanced Monofocal, Monofocal, and Trifocal Intraocular Lenses

ABSTRACT

Purpose@#To compare the clinical outcomes of patients given an enhanced monofocal intraocular lens (IOL) (Isopure; PhysIOL, Liege, Belgium), and monofocal, and trifocal IOLs. @*Methods@#Patients who underwent cataract surgery with bilateral implantation of monofocal Vivinex IOLs, enhanced monofocal Isopure IOLs, and trifocal Panoptix IOLs were included. Three months postoperatively, the uncorrected distance visual acuity (UDVA), intermediate visual acuity (UIVA), and near visual acuity (UNVA), as well as the spherical equivalent (SE) were determined. Photic symptoms were explored via a questionnaire. @*Results@#The postoperative SE and UDVA did not differ significantly among the three groups (p = 0.100 and 0.204 respectively). The mean UIVAs (logMAR) were 0.61 ± 0.14, 0.3 ± 0.1, and 0.14 ± 0.11 in the Vivinex, Isopure, and Panoptix groups respectively. The Isopure group exhibited a significantly better UIVA than the Vivinex group (p < 0.001) and the Panoptix group exhibited a significantly better UIVA than either the Vivinex or Isopure group (p = 0.002 and < 0.001 respectively). The mean UNVAs (logMAR) were 0.68 ± 0.16, 0.57 ± 0.19, and 0.17 ± 0.12 for the Vivinex, Isopure, and Panoptix groups respectively. There was no significant UNVA difference between the Vivinex and Isopure groups (p = 0.185) but the UNVA of the Panoptix group was significantly better than the UNVAs of the Vivinex and Isopure groups (both p < 0.001). There was no significant difference in photic symptoms between the Vivinex and Isopure groups (p = 0.980); however, the Panoptix group evidenced significantly more severe symptoms than did the other two groups (p = 0.021 and 0.042 respectively). @*Conclusions@#Enhanced monofocal Isopure IOL showed superior intermediate vision compared to Vivinex monofocal IOL, and inferior intermediate and near visual acuity compared Panoptix trifocal IOL, but with fewer photic symptoms.